Leqembi Pen subcutaneous form launches in Japan for Alzheimer's
Eisai has launched Leqembi Pen, a subcutaneous form of lecanemab, in Japan, the second country after the US, for home use, BioArctic reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Reuters and TradingView, Eisai, the partner of BioArctic, announced the launch of Leqembi Pen, a subcutaneous form of lecanemab, for early Alzheimer's disease in Japan. Japan is the second country after the US where the subcutaneous form of Leqembi is available. The drug was approved in the country on September 16, 2026 and has been added to Japan's National Health Insurance drug price list.
Leqembi Pen uses an autoinjector and gives patients a once-weekly injection option alongside intravenous treatment every two weeks at a medical facility. The approved dose is 500 mg, given through two pens. It is the first and only anti-amyloid treatment in Japan that can be administered at home. MRI monitoring for amyloid-related imaging abnormalities is still required before treatment starts and at set intervals afterward.
why it matters
The news concerns one drug and one company, so it is unlikely to move broader markets. For BioArctic, the launch extends sales reach: the company bears no development costs for lecanemab in Alzheimer's and receives sales milestone payments and royalties on global sales.
tags
instruments
sources
- BioArctic: Leqembi Pen Subcutaneous Treatment Launched In Japan — Reuters, 13 November 2026 at 07:05 UTC
- Leqembi® Pen subcutaneous treatment launched in Japan — TradingView, 13 November 2026 at 07:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗